postmenopausal osteoporosis

Summary

Summary: Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.

Top Publications

  1. pmc Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice
    Oliver Bock
    Center for Muscle and Bone Research, Campus Benjamin Franklin, Charite University Medicine Berlin, Berlin, Germany
    Clin Interv Aging 3:279-97. 2008
  2. ncbi Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis
    Xiaodong Li
    Department of Metabolic Disorders, Amgen, Thousand Oaks, California 91320 1799, USA
    J Bone Miner Res 24:578-88. 2009
  3. ncbi Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group
    M R McClung
    Oregon Osteoporosis Center and Providence Medical Center, Portland 97213, USA
    N Engl J Med 344:333-40. 2001
  4. ncbi Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
    R M Neer
    Massachusetts General Hospital and Harvard Medical School, Boston, USA
    N Engl J Med 344:1434-41. 2001
  5. ncbi Treatment of postmenopausal osteoporosis
    Pierre D Delmas
    Claude Bernard University of Lyon and INSERM Research Unit 403, France
    Lancet 359:2018-26. 2002
  6. ncbi Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
    Dennis M Black
    University of California, San Francisco, San Francisco, CA 94107, USA
    N Engl J Med 356:1809-22. 2007
  7. ncbi Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial
    Dennis M Black
    San Francisco Coordinating Center, Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94107, USA
    JAMA 296:2927-38. 2006
  8. ncbi A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis
    Hiroshi Hagino
    Rehabilitation Division and School of Health Science, Tottori University, Yonago, Tottori 683 8504, Japan
    Bone 44:1078-84. 2009
  9. ncbi Role of antioxidant systems, lipid peroxidation, and nitric oxide in postmenopausal osteoporosis
    Salih Ozgocmen
    Division of Rheumatology, Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Firat University, Firat Tip Merkezi, FTR AD, Romatoloji BD, 23119, Elazig, Turkey
    Mol Cell Biochem 295:45-52. 2007
  10. ncbi Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women
    Robert R Recker
    Creighton University School of Medicine, Omaha, Neb, USA
    Mayo Clin Proc 80:856-61. 2005

Detail Information

Publications318 found, 100 shown here

  1. pmc Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice
    Oliver Bock
    Center for Muscle and Bone Research, Campus Benjamin Franklin, Charite University Medicine Berlin, Berlin, Germany
    Clin Interv Aging 3:279-97. 2008
    ..ibandronate, risedronate, and zoledronate are considered today a treatment of first choice in postmenopausal osteoporosis. However, treatment effects in an individual patient and cost-effectiveness in public health ..
  2. ncbi Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis
    Xiaodong Li
    Department of Metabolic Disorders, Amgen, Thousand Oaks, California 91320 1799, USA
    J Bone Miner Res 24:578-88. 2009
    ..neutralizing monoclonal antibody (Scl-AbII) for testing in an aged ovariectomized rat model of postmenopausal osteoporosis. Six-month-old female rats were ovariectomized and left untreated for 1 yr to allow for significant ..
  3. ncbi Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group
    M R McClung
    Oregon Osteoporosis Center and Providence Medical Center, Portland 97213, USA
    N Engl J Med 344:333-40. 2001
    ..Risedronate increases bone mineral density in elderly women, but whether it prevents hip fracture is not known...
  4. ncbi Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
    R M Neer
    Massachusetts General Hospital and Harvard Medical School, Boston, USA
    N Engl J Med 344:1434-41. 2001
    ..CONCLUSIONS: Treatment of postmenopausal osteoporosis with parathyroid hormone (1-34) decreases the risk of vertebral and nonvertebral fractures; increases ..
  5. ncbi Treatment of postmenopausal osteoporosis
    Pierre D Delmas
    Claude Bernard University of Lyon and INSERM Research Unit 403, France
    Lancet 359:2018-26. 2002
    The aim of treatment of postmenopausal osteoporosis is to reduce the frequency of vertebral and non-vertebral fractures (especially at the hip), which are responsible for morbidity associated with the disease...
  6. ncbi Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
    Dennis M Black
    University of California, San Francisco, San Francisco, CA 94107, USA
    N Engl J Med 356:1809-22. 2007
    ..We assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period...
  7. ncbi Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial
    Dennis M Black
    San Francisco Coordinating Center, Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94107, USA
    JAMA 296:2927-38. 2006
    The optimal duration of treatment of women with postmenopausal osteoporosis is uncertain.
  8. ncbi A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis
    Hiroshi Hagino
    Rehabilitation Division and School of Health Science, Tottori University, Yonago, Tottori 683 8504, Japan
    Bone 44:1078-84. 2009
    ..In a randomized, active-controlled, double-blinded, multicenter study, the efficacy and safety of minodronate were examined and compared to that of alendronate...
  9. ncbi Role of antioxidant systems, lipid peroxidation, and nitric oxide in postmenopausal osteoporosis
    Salih Ozgocmen
    Division of Rheumatology, Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Firat University, Firat Tip Merkezi, FTR AD, Romatoloji BD, 23119, Elazig, Turkey
    Mol Cell Biochem 295:45-52. 2007
    ..of antioxidant enzymes, lipid peroxidation end-products, and nitric oxide (NO) levels in women with postmenopausal osteoporosis (PMO)...
  10. ncbi Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women
    Robert R Recker
    Creighton University School of Medicine, Omaha, Neb, USA
    Mayo Clin Proc 80:856-61. 2005
    ..To compare medication adherence with daily vs weekly bisphosphonate dosing for the treatment or prevention of osteoporosis in a broad US retail pharmacy database population...
  11. ncbi Validity of self-report for fractures among a multiethnic cohort of postmenopausal women: results from the Women's Health Initiative observational study and clinical trials
    Zhao Chen
    University of Arizona, Tucson, AZ, USA
    Menopause 11:264-74. 2004
    ..The purpose of this study is to examine the validity of, and factors associated with, the accuracy of self-report (participant-report and proxy-report) for fractures...
  12. ncbi Requirements for DXA for the management of osteoporosis in Europe
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 16:229-38. 2005
    ..The total direct costs were estimated at 31.7 billion Euros (21.165 billion UK pounds), which were expected to increase to 76.7 billion Euros (51.1 billion UK pounds) in 2050 based on the expected changes in the demography of Europe...
  13. pmc Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis
    Joel S Finkelstein
    Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Clin Endocrinol Metab 95:1838-45. 2010
    ..Teriparatide increases both bone formation and bone resorption...
  14. ncbi Strontium ranelate: a review of its use in the treatment of postmenopausal osteoporosis
    Emma D Deeks
    Adis, Auckland, New Zealand
    Drugs 70:733-59. 2010
    ..Protos, Protaxos, Bivalos, Osseor), and its efficacy and tolerability in the treatment of patients with postmenopausal osteoporosis. Strontium ranelate is a divalent strontium salt of ranelic acid that is capable of increasing bone ..
  15. ncbi Denosumab in postmenopausal women with low bone mineral density
    Michael R McClung
    Providence Portland Medical Center, Portland, Oreg, USA
    N Engl J Med 354:821-31. 2006
    ..The fully human monoclonal antibody denosumab (formerly known as AMG 162) binds RANKL with high affinity and specificity and inhibits RANKL action...
  16. ncbi Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study
    Louis Georges Ste-Marie
    Centre de Recherche du CHUM, Hopital Saint Luc, Montreal, Quebec, Canada
    Clin Ther 31:272-85. 2009
    Risedronate 5 mg/d is approved by the US Food and Drug Administration for the treatment and prevention of postmenopausal osteoporosis. Once-monthly dosing options might increase treatment compliance and persistence.
  17. ncbi Compliance with drug therapy for postmenopausal osteoporosis
    D Weycker
    Policy Analysis Inc PAI, Four Davis Court, Brookline, MA, 02445, USA
    Osteoporos Int 17:1645-52. 2006
    ..Patient compliance with pharmacotherapy for osteoporosis is typically poor in clinical practice; less frequent dosing with bisphosphonates may improve compliance...
  18. ncbi Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study
    John A Eisman
    Garvan Institute of Medical Research, St Vincent s Campus and University of New South Wales, Sydney, Australia
    J Rheumatol 35:488-97. 2008
    ..study was designed to identify the optimal ibandronate IV injection schedule for the treatment of postmenopausal osteoporosis by comparing the efficacy and tolerability of 2- and 3-monthly injections with the previously evaluated ..
  19. ncbi The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial
    Jackie A Clowes
    Bone Metabolism Group, University of Sheffield, Sheffield, United Kingdom S57 AU
    J Clin Endocrinol Metab 89:1117-23. 2004
    ..36; P = 0.002). In conclusion, monitoring of patients increased adherence to therapy by 57% at 1 yr. Increased adherence to therapy increased the effectiveness of raloxifene therapy determined using surrogate end points...
  20. ncbi Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial
    S R Cummings
    Department of Epidemiology and Biostatistics, University of California, San Francisco 94105, USA
    JAMA 280:2077-82. 1998
    ..Alendronate sodium reduces fracture risk in postmenopausal women who have vertebral fractures, but its effects on fracture risk have not been studied for women without vertebral fractures...
  21. ncbi The ovariectomized, mature rat model of postmenopausal osteoporosis: an assessment of the bone sparing effects of curcumin
    D L French
    Department of Radiology, McMaster University, Hamilton, Ontario, Canada
    Phytomedicine 15:1069-78. 2008
    ..The objectives of this study were to evaluate an animal model of postmenopausal osteoporosis and to search for evidence that curcumin reduces bone mineral losses in a dose-dependent manner when ..
  22. pmc Pathogenesis of osteoporosis: concepts, conflicts, and prospects
    Lawrence G Raisz
    University of Connecticut Health Center, Musculoskeletal Institute, Farmington, Connecticut 06032, USA
    J Clin Invest 115:3318-25. 2005
    ..However, new and more effective approaches are likely to emerge from a better understanding of the regulators of bone cell function...
  23. ncbi A prospective study of bone loss in menopausal Australian-born women
    J R Guthrie
    Department of Psychiatry, Royal Melbourne Hospital, Victoria, Australia
    Osteoporos Int 8:282-90. 1998
    ..05), such that women with higher BMI had less bone loss. In conclusion, during the time of transition from peri- to post-menopause, women had accelerated BMD loss at both the hip and spine...
  24. ncbi Back extensor strength and lumbar spinal mobility are predictors of quality of life in patients with postmenopausal osteoporosis
    N Miyakoshi
    Division of Orthopedic Surgery, Department of Neuro and Locomotor Science, Akita University School of Medicine, 1 1 1 Hondo, Akita 010 8543, Japan
    Osteoporos Int 18:1397-403. 2007
    ..Back extensor strength and lumbar spinal mobility were the most important factors for QOL in these patients...
  25. ncbi Association of molecular variants, haplotypes, and linkage disequilibrium within the human vitamin D-binding protein (DBP) gene with postmenopausal bone mineral density
    Yoichi Ezura
    Department of Molecular Biology, Institute of Gerontology, Nippon Medical School, Kawasaki, Japan
    J Bone Miner Res 18:1642-9. 2003
    ..029, p = 0.005). These results indicate a complex combined effect of several SNPs within the DBP gene that might underlie susceptibility to low radial BMD and osteoporosis...
  26. ncbi Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial
    Karen M Prestwood
    Center on Aging, University of Connecticut Health Center, Farmington 06030, USA
    JAMA 290:1042-8. 2003
    ..Estrogen therapy is known to prevent osteoporosis, but studies have shown that conventional doses increase adverse events. Whether lower doses, one quarter of standard treatment, prevent bone loss is not known...
  27. ncbi At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis
    F Borgstrom
    Medical Management Centre, Karolinska Institutet, Stockholm, Sweden
    Osteoporos Int 17:1459-71. 2006
    ..Intervention thresholds (ITs), the 10-year hip fracture risk at which treatment can be considered to be cost-effective, have previously been estimated for Sweden and the UK...
  28. ncbi Vitamin D, parathyroid hormone levels and bone mineral density in community-dwelling older women: the Rancho Bernardo Study
    Denise G Von Muhlen
    Division of Epidemiology, Department of Family and Preventive Medicine, University of California, San Diego, La Jolla, CA 92093, USA
    Osteoporos Int 16:1721-6. 2005
    ..20). However, after the threshold vitamin D level of 120 nmol/l, all PTH values were below 65 ng/l. Further studies are necessary to identify the optimal vitamin D levels necessary to prevent secondary hyperparathyroidism...
  29. ncbi Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study
    J Y Reginster
    Department of Epidemiology, Public Health and Health Economics, University of Liege, CHU Centre Ville, 45 Quai Godefroid Kurth, 4020 Liege, Belgium
    J Clin Endocrinol Metab 90:2816-22. 2005
    ....
  30. ncbi Biomarkers of bone health and osteoporosis risk
    Richard Eastell
    Academic Unit of Bone Metabolism, University of Sheffield, Metabolic Bone Centre, Sorby Wing, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK
    Proc Nutr Soc 67:157-62. 2008
    ....
  31. ncbi Periosteal bone formation--a neglected determinant of bone strength
    Ego Seeman
    Austin Hospital, University of Melbourne, Melbourne, Australia
    N Engl J Med 349:320-3. 2003
  32. ncbi The population burden of fractures originates in women with osteopenia, not osteoporosis
    J A Pasco
    Department of Clinical and Biomedical Sciences, Barwon Health, The Geelong Hospital, The University of Melbourne, P O Box 281, Geelong 3220, Australia
    Osteoporos Int 17:1404-9. 2006
    ..The aim of this study was to determine the proportion of the population burden of fragility fractures arising from women at modest risk for fracture...
  33. ncbi Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial
    Jean Yves Reginster
    University of Liege, Liege, Belgium
    Arthritis Rheum 58:1687-95. 2008
    ..This study was undertaken to assess the effect of strontium ranelate on nonvertebral and vertebral fractures in postmenopausal women with osteoporosis in a 5-year, double-blind, placebo-controlled trial...
  34. ncbi Relationship between body composition and bone mineral density in women with and without osteoporosis: relative contribution of lean and fat mass
    Saverio Gnudi
    Modulo Dipartimentale di Medicina Interna, Istituti Ortopedici Rizzoli, Via Pupilli 1, 40136 Bologna, Italy
    J Bone Miner Metab 25:326-32. 2007
    ..05), while TLM did not. In conclusion, our data indicate that both TFM and TLM affect bone density, with different physiological/pathological conditions modulating this relationship...
  35. ncbi The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis
    Pierre J Meunier
    Department of Rheumatology and Bone Diseases, Edouard Herriot Hospital, Lyons, France
    N Engl J Med 350:459-68. 2004
    ....
  36. ncbi Performance of risk indices for identifying low bone density in postmenopausal women
    Piet Geusens
    Biomedical Research Institute, Limburg University, Diepenbeek, Belgium
    Mayo Clin Proc 77:629-37. 2002
    ..To examine the ability of 4 published osteoporosis risk indices to identify women with low bone density...
  37. ncbi [Diagnosis and treatment of postmenopausal osteoporosis and osteoporosis in men. German Guidelines Update 2006]
    A A Kurth
    Orthopadische Universitatsklinik, Stiftung Friedrichsheim, Marienburgstrasse 2, 60528 Frankfurt Main
    Orthopade 36:683-90; quiz 691. 2007
    ....
  38. ncbi Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group
    D M Black
    Department of Epidemiology and Biostatistics, University of California, San Francisco 94105, USA
    J Clin Endocrinol Metab 85:4118-24. 2000
    ..Furthermore, reduction in risk is evident early in the course of treatment. This pooled analysis provides a more precise estimate of the antifracture efficacy of alendronate in women with osteoporosis than that in prior reports...
  39. ncbi Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators
    B Ettinger
    Division of Research, Kaiser Permanente, Oakland, Calif 94611 5400, USA
    JAMA 282:637-45. 1999
    ..Raloxifene hydrochloride, a selective estrogen receptor modulator, prevents bone loss in postmenopausal women, but whether it reduces fracture risk in these women is not known...
  40. ncbi Residual lifetime risk of fractures in women and men
    Nguyen D Nguyen
    Bone and Mineral Research Program, Garvan Institute of Medical Research, St Vincent s Hospital, Sydney, New South Wales, Australia
    J Bone Miner Res 22:781-8. 2007
    ..Among those with BMD T-scores < or = -2.5, the risks increased to 65% in women and 42% in men...
  41. ncbi Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial
    O Strom
    European Health Economics, Vasagaatn 38 2 tr, SE 111 20, Stockholm, Sweden
    Osteoporos Int 18:1047-61. 2007
    ..Cost-effectiveness of treatment was assessed in nine European countries in a Markov model and was generally found to be cost effective in women with a previous spine fracture...
  42. ncbi Short-term menatetrenone therapy increases gamma-carboxylation of osteocalcin with a moderate increase of bone turnover in postmenopausal osteoporosis: a randomized prospective study
    Masataka Shiraki
    Research Institute and Practice for Involutional Disease, 1610 1 Meisei, Misato, Azumino, Nagano 399 8101, Japan
    J Bone Miner Metab 27:333-40. 2009
    ..Further investigations are required to determine whether the effects of menatetrenone on bone turnover are associated with fracture prevention...
  43. ncbi Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene
    Michael R McClung
    Oregon Osteoporosis Center, Portland, OR 97213, USA
    Menopause 13:377-86. 2006
    ..The objective of this study was to compare the effects of lasofoxifene with raloxifene and placebo on indices of bone health in postmenopausal women...
  44. ncbi [Biochemical markers of bone remodeling: recent data of their applications in managing postmenopausal osteoporosis]
    Afef Bahlous
    Service de Biochimie Clinique Hôpital Charles Nicolle Pr Chalbi Belkahia Faculté de Médecine de Tunis
    Tunis Med 84:751-7. 2006
    ..The principal application fields of biochemical markers in postmenopausal osteoporosis, in combination with the measurement of the bone mineral mass, are primarily the monitoring of anti-..
  45. ncbi Significant reduction in risk of falls and back pain in osteoporotic-kyphotic women through a Spinal Proprioceptive Extension Exercise Dynamic (SPEED) program
    Mehrsheed Sinaki
    Department of Physical Medicine and Rehabilitation, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 80:849-55. 2005
    ....
  46. ncbi Medication adherence: a challenge for patients with postmenopausal osteoporosis and other chronic illnesses
    Deborah T Gold
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    J Manag Care Pharm 12:S20-5; quiz S26-8. 2006
    ....
  47. ncbi Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial
    P J Meunier
    Hopital Edouard Herriot, 69437 Lyon, France
    J Clin Endocrinol Metab 87:2060-6. 2002
    ..was to investigate the efficacy and safety of different doses of SR, a novel agent in the treatment of postmenopausal osteoporosis. A randomized, multicenter, double-blind, placebo-controlled trial was undertaken in 353 osteoporotic ..
  48. ncbi A simple tool to identify asian women at increased risk of osteoporosis
    L K Koh
    Department of Endocrinology, Singapore General Hospital, Singapore
    Osteoporos Int 12:699-705. 2001
    ..We conclude that our index performed well for classifying the risk of osteoporosis among postmenopausal Asian women and applying it would result in more prudent use of BMD technology...
  49. ncbi Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International
    P N Sambrook
    Institue of Bone and Joint Research, Royal North Shore Hospital, University of Sydney, St Leonards NSW, Australia
    J Intern Med 255:503-11. 2004
    ..This study was undertaken to compare the efficacy and tolerability of alendronate to raloxifene in postmenopausal women with low-bone density...
  50. ncbi Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 19:1395-408. 2008
    ..Assessment and intervention thresholds are developed and proposed in men aged over 50 years and postmenopausal women for the UK based on fracture probability from the WHO fracture risk assessment tool (FRAX)...
  51. ncbi Postmenopausal osteoporosis as a failure of bone's adaptation to functional loading: a hypothesis
    L Lanyon
    Department of Veterinary Basic Sciences, The Royal Veterinary College, London, United Kingdom
    J Bone Miner Res 16:1937-47. 2001
    ..It is probably useful to consider the diminished ability to maintain bone strength in postmenopausal osteoporosis as a failure of this mechanism...
  52. ncbi Influence of type 2 diabetes mellitus on bone mineral density response to bisphosphonates in late postmenopausal osteoporosis
    Selcuk Dagdelen
    Department of Endocrinology and Metabolism, Hacettepe University School of Medicine, Ankara, Turkey
    Adv Ther 24:1314-20. 2007
    Bisphosphonates are effective agents for postmenopausal osteoporosis, but their efficacy in patients with type 2 diabetes mellitus (DM) is not known...
  53. ncbi The role of trace minerals in the pathogenesis of postmenopausal osteoporosis and a new effect of calcitonin
    Ali Gur
    Physical Medicine and Rehabilitation, Dicle University School of Medicine, Diyarbakir, Turkey
    J Bone Miner Metab 20:39-43. 2002
    ..Very few longitudinal studies have reported the effects of calcitonin therapy on trace minerals in postmenopausal osteoporosis despite the documented involvement of trace minerals in normal skeletal metabolism...
  54. ncbi [The regulation of hypoxia inducible factor-1alpha on osteoblast function in postmenopausal osteoporosis]
    Xiao Dong Liu
    Shanghai Institute of Traumatology and Orthopedics, Department of Orthopedics, Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai 200025, China
    Zhonghua Wai Ke Za Zhi 45:1274-8. 2007
    To study the regulation of hypoxia inducible factor-1alpha (HIF-1alpha) on osteoblast function in postmenopausal osteoporosis.
  55. ncbi The effects of strontium ranelate in Asian women with postmenopausal osteoporosis
    J S Hwang
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Linkou, Chlayi, Kaohsiung, Taiwan, ROC
    Calcif Tissue Int 83:308-14. 2008
    ..Safety assessment revealed adverse events were mild and not significantly different from placebo...
  56. ncbi Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY study
    Elisabeth Sornay-Rendu
    INSERM Research Unit 403, Pavillon F, E Herriot Hospital, 69437 Lyon Cedex 03, France
    Bone 33:159-66. 2003
    ....
  57. ncbi Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density
    B Lawrence Riggs
    J Bone Miner Res 17:11-4. 2002
  58. ncbi Effects of denosumab on bone mineral density and bone turnover in postmenopausal women
    Henry G Bone
    Michigan Bone and Mineral Clinic, 22201 Moross Road, Detroit, MI 48236, USA
    J Clin Endocrinol Metab 93:2149-57. 2008
    ..Denosumab is an investigational fully human monoclonal antibody against receptor activator of nuclear factor-kappaB ligand, a mediator of osteoclastogenesis and osteoclast survival...
  59. ncbi A randomized, prospective study of the effects of Tai Chi Chun exercise on bone mineral density in postmenopausal women
    Kaiming Chan
    Department of Orthopaedics and Traumatology, Chinese University of Hong Kong, Hong Kong
    Arch Phys Med Rehabil 85:717-22. 2004
    ..To evaluate the potential benefits of programmed Tai Chi Chun (TCC) exercise on the weight-bearing bones of early postmenopausal women...
  60. ncbi Meta-analysis of walking for preservation of bone mineral density in postmenopausal women
    Marrissa Martyn-St James
    Carnegie Faculty of Sport and Education, Leeds Metropolitan University, Room 202, Fairfax Hall, Headingley Campus, Leeds LS6 3QT, UK
    Bone 43:521-31. 2008
    ..Other forms of exercise that provide greater targeted skeletal loading may be required to preserve bone mineral density in this population...
  61. ncbi Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis
    P Szulc
    INSERM Research Unit 831, Hopital Edouard Herriot, Lyon, France
    Osteoporos Int 19:1683-704. 2008
    The aim was to analyse data on the use of biochemical bone turnover markers (BTM) in postmenopausal osteoporosis.
  62. ncbi Osteocalcin: genetic and physical mapping of the human gene BGLAP and its potential role in postmenopausal osteoporosis
    M H Raymond
    Department of Preventive Medicine and Environmental Health, University of Iowa, Iowa City, Iowa 52242, USA
    Genomics 60:210-7. 1999
    ..03). Our data suggest that genetic variation at the osteocalcin locus impacts BMD levels in the postmenopausal period and may predispose some women to osteoporosis...
  63. ncbi Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters
    Monique Arlot
    Laboratoire d Histodynamique Osseuse and INSERM Unit 403, Faculty of Medicine R Laennec, Lyon, France
    J Bone Miner Res 20:1244-53. 2005
    ..Biopsies were obtained from 42 patients. Indices of bone formation were significantly higher after 6 or 18 months of teriparatide compared with alendronate treatment...
  64. ncbi Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD
    Nelson B Watts
    University of Cincinnati Bone Health and Osteoporosis Center, Ohio, USA
    J Bone Miner Res 20:2097-104. 2005
    ..Change in BMD did not influence the magnitude of risedronate's effect on nonvertebral fractures; the incidence of nonvertebral fractures was equally low in treated patients whose BMD increased or decreased...
  65. ncbi Circulating levels of osteoclast activating cytokines, interleukin-11 and transforming growth factor-beta2, as valuable biomarkers for the assessment of bone turnover in postmenopausal osteoporosis
    Mohamed Shaarawy
    Endocrinology and Maternal Biochemistry Unit, Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, Cairo, Egypt
    Clin Lab 49:625-36. 2003
    ..IL-11) and transforming growth factor-beta2 (TGF-beta2) in the assessment of bone turnover in postmenopausal osteoporosis (PO)...
  66. pmc Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday
    J R Curtis
    Center for Education and Research on Therapeutics of Musculoskeletal Disorders, University of Alabama at Birmingham, Birmingham, AL, USA
    Osteoporos Int 19:1613-20. 2008
    ....
  67. ncbi Bone turnover markers in the management of postmenopausal osteoporosis
    Jacques P Brown
    Universite Laval, Quebec, QC, Canada
    Clin Biochem 42:929-42. 2009
    ....
  68. ncbi Separate and combined value of bone mass and gait speed measurements in screening for hip fracture risk: results from the EPIDOS study. Epidémiologie de l'Ostéoporose
    P Dargent-Molina
    INSERM Unit 149, Villejuif, France
    Osteoporos Int 9:188-92. 1999
    ..The sensitivity of the available screening tools is low, even when they are combined: to obtain a sensitivity of about 80%, approximately 50% of the population must be considered to be at high risk...
  69. ncbi A Markov model simulation of the impact of treatment persistence in postmenopausal osteoporosis
    François Emery Cotté
    CERMES, INSERM U750, National Institute of Health and Medical Research, 7 rue Guy Moquet, Villejuif, France
    Med Decis Making 29:125-39. 2009
    ..number of incident osteoporotic fractures by age for the overall population of women with diagnosed postmenopausal osteoporosis in France (mean age, 71.1 years +/-9.6; range, 50-96 years)...
  70. ncbi Use of biochemical markers of bone turnover in the management of postmenopausal osteoporosis
    Pauline M Camacho
    Division of Endocrinology and Metabolism, Loyola University Stritch School of Medicine, Maywood, IL 60153, USA
    Clin Chem Lab Med 46:1345-57. 2008
    ..The aim of this review is to present data which helps elucidate the current role and limitation of BTMs in the management of osteoporosis...
  71. ncbi Practical guidance for the management of aromatase inhibitor-associated bone loss
    P Hadji
    Department of Gynecology, Philipps University of Marburg, Marburg, Germany
    Ann Oncol 19:1407-16. 2008
    ....
  72. ncbi The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation
    S R Cummings
    Department of Medicine, University of California, San Francisco, USA
    JAMA 281:2189-97. 1999
    ..Raloxifene hydrochloride is a selective estrogen receptor modulator that has antiestrogenic effects on breast and endometrial tissue and estrogenic effects on bone, lipid metabolism, and blood clotting...
  73. ncbi The effects of Tai Chi on bone mineral density in postmenopausal women: a systematic review
    Peter M Wayne
    New England School of Acupuncture, Watertown, MA, USA
    Arch Phys Med Rehabil 88:673-80. 2007
    ..To evaluate the evidence for Tai Chi as an intervention to reduce rate of bone loss in postmenopausal women...
  74. ncbi Risk factors for a first-incident radiographic vertebral fracture in women > or = 65 years of age: the study of osteoporotic fractures
    Michael C Nevitt
    Department of Epidemiology and Biostatistics, University of California, San Francisco, California 94105, USA
    J Bone Miner Res 20:131-40. 2005
    ..Risk factors and low BMD should be useful to help focus efforts to prevent these fractures...
  75. ncbi Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment
    Richard Prince
    Department of Endocrinology and Diabetes and University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, Australia
    J Bone Miner Res 20:1507-13. 2005
    ..The hazard ratio for combined teriparatide group (20 and 40 microg) for the 50-month period after baseline was 0.57 (p = 0.002), suggesting a sustained effect in reducing the risk of nonvertebral fragility fracture...
  76. ncbi Vibration exercise makes your muscles and bones stronger: fact or fiction?
    Marco Cardinale
    Olympic Medical Institute, Northwick Park Hospital, Harrow, UK
    J Br Menopause Soc 12:12-8. 2006
    ..The physiological mechanisms involved in the adaptive responses to vibration exercise are discussed and suggestions for future studies are made...
  77. ncbi Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment
    E S Siris
    Toni Stabile Osteoporosis Center, Columbia Presbyterian Medical Center, 180 Fort Washington Ave, New York, NY 10032 3784, USA
    JAMA 286:2815-22. 2001
    ..Large segments of the population at risk for osteoporosis and fracture have not been evaluated, and the usefulness of peripheral measurements for short-term prediction of fracture risk is uncertain...
  78. ncbi Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis
    R Lindsay
    Helen Hayes Hospital, West Havershaw, NY, USA
    Osteoporos Int 20:943-8. 2009
    ..In postmenopausal women with osteoporosis, increased duration of teriparatide versus placebo treatment was associated with a progressive decrease in the rates of nonvertebral fragility fractures and back pain...
  79. ncbi Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis
    E F Eriksen
    University Department of Endocrinology, Aarhus Amtssygehus, Denmark
    Bone 31:620-5. 2002
    ..of 3 years of oral risedronate treatment on bone quality and remodeling were assessed in women with postmenopausal osteoporosis. Transiliac bone biopsies were obtained at baseline and after treatment with placebo or risedronate 5 ..
  80. ncbi Fracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO)
    C Cooper
    MRC Epidemiology Resource Centre, Southampton General Hospital, Southampton, UK
    Osteoporos Int 19:493-501. 2008
    ....
  81. ncbi Persistence with teriparatide in patients with osteoporosis: the UK experience
    N K Arden
    MRC Epidemiology Resource Centre, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK
    Osteoporos Int 17:1626-9. 2006
    ..The objective of this paper was to determine the persistence with teriparatide at 12 months in all patients in the UK who were prescribed the treatment since its launch...
  82. ncbi Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis
    S T Harris
    University of California, San Francisco, California 94117, USA
    Curr Med Res Opin 20:757-64. 2004
    ..The efficacy and tolerability of risedronate once-a-week dosing (35 and 50mg) were compared with risedronate daily dosing (5mg) in a 2-year study in women with osteoporosis...
  83. ncbi Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate
    R Eastell
    Bone Metabolism Group, University of Sheffield, Sheffield, United Kingdom
    J Bone Miner Res 18:1051-6. 2003
    ..The decrease in bone resorption in patients taking risedronate accounts for a large proportion of the reduction in fracture risk. There may be a level of bone resorption reduction below which there is no further fracture benefit...
  84. ncbi Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women
    Emmanuel Papadimitropoulos
    Endocr Rev 23:560-9. 2002
    ..To review the effect of vitamin D on bone density and fractures in postmenopausal women...
  85. ncbi Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis
    Olof Johnell
    Department of Orthopaedics, Universiteitssjukhuset MAS, Malmø, Sweden
    J Clin Endocrinol Metab 87:985-92. 2002
    ..RLX+ALN reduced bone turnover more than either drug alone, resulting in greater BMD increment, but whether this difference reflects better fracture risk reduction was not assessed in this study...
  86. ncbi Effects of calcitonin, risedronate, and raloxifene on erythrocyte antioxidant enzyme activity, lipid peroxidation, and nitric oxide in postmenopausal osteoporosis
    Salih Ozgocmen
    Division of Rheumatology, Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Firat University, Elazig, Turkey
    Arch Med Res 38:196-205. 2007
    ..antioxidant enzyme activities, lipid peroxidation, and nitric oxide levels (NO) in women with postmenopausal osteoporosis (PMO) and non-porotic postmenopausal healthy controls and to assess the relationship between bone ..
  87. ncbi Yearly zoledronic acid in postmenopausal osteoporosis
    Roger Karam
    N Engl J Med 357:712-3; author reply 714-5. 2007
  88. ncbi The serum level of bone-specific alkaline phosphatase activity is associated with aortic calcification in osteoporosis patients
    Kousuke Iba
    Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine, South 1, West 16, Chuo Ku, Sapporo, Japan
    J Bone Miner Metab 22:594-6. 2004
    ..Bone-specific alkaline phosphatase is the most important marker for osteoblast differentiation; furthermore, the serum level of its activity may reflect the process of calcification of the aorta in osteoporosis patients...
  89. ncbi Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study
    R R Recker
    Creighton University School of Medicine, Creighton University, Omaha, Nebraska, USA
    Osteoporos Int 15:231-7. 2004
    ..to reduce levels of biochemical markers of bone turnover in a phase III randomized study in women with postmenopausal osteoporosis (PMO)...
  90. ncbi A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial
    Kazuhiro Kushida
    Department of Orthopedics, Hamamatsu University School of Medicine, 1 20 1 Handayama, 431 3192, Hamamatsu, Japan
    J Bone Miner Metab 22:469-78. 2004
    ..Daily oral risedronate (2.5 mg) was shown to provide an effective therapy for involutional osteoporosis in Japanese patients with good tolerability...
  91. ncbi Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial
    Susan L Greenspan
    University of Pittsburgh, Osteoporosis Prevention and Treatment Center, Kaufmann Medical Building, Suite 1110, 3471 Fifth Avenue, Pittsburgh, PA 15213, USA
    Ann Intern Med 137:875-83. 2002
    ..Changes in bone mineral density after discontinuation of therapy have not been compared directly...
  92. ncbi Changes in bone remodeling rate influence the degree of mineralization of bone
    G Boivin
    Inserm Unite 403, Faculté de Médecine R Laennec, Hopital Edouard Herriot, Lyon, France
    Connect Tissue Res 43:535-7. 2002
    ..In contrast, an activation of bone remodeling as in primary hyperparathyroidism lowered the mean DMB...
  93. ncbi The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 18:1033-46. 2007
    ..The combination of clinical risk factors and BMD provide higher specificity and sensitivity than either alone. INTRODUCTION AND HYPOTHESES: To develop a risk assessment tool based on clinical risk factors (CRFs) with and without BMD...
  94. ncbi Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem
    Joyce A Cramer
    Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06516 2770, USA
    Am J Med 119:S12-7. 2006
    ..It should be assumed that every patient receiving therapy for osteoporosis needs regular reinforcement of the importance of continuing therapy...
  95. ncbi Tai chi for osteoporosis: a systematic review
    M S Lee
    Complementary Medicine, Peninsula Medical School, Universities of Exeter and Plymouth, 25 Victoria Park Road, Exeter, EX2 4NT, UK
    Osteoporos Int 19:139-46. 2008
    ..The purpose of this systematic review was to evaluate evidence from controlled clinical trials testing the effectiveness of tai chi for osteoporosis...
  96. ncbi Effect of 6-month whole body vibration training on hip density, muscle strength, and postural control in postmenopausal women: a randomized controlled pilot study
    Sabine M P Verschueren
    Laboratory of Motor Control, Department of Kinesiology, Faculteit Lichamelijke Opvoeding en Kinesitherapie, Katholieke Universiteit, Leuven, Belgium
    J Bone Miner Res 19:352-9. 2004
    ..Vibration training significantly increased BMD of the hip. These findings suggest that WBV training might be useful in the prevention of osteoporosis...
  97. ncbi Biochemical markers of bone turnover and response of bone mineral density to intervention in early postmenopausal women: an experience in a clinical laboratory
    L O Chailurkit
    Division of Endocrinology and Metabolism, Department of Medicine, Ramathibodi Hopital, Mahidol University, Rama VI Road, Bangkok 10400, Thailand
    Clin Chem 47:1083-8. 2001
    ..Our aim in this study was to investigate the use of bone markers for monitoring of intervention for bone loss in early postmenopausal women and to assess the relationships between these markers and changes in bone mineral density (BMD)...
  98. ncbi Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis
    Ann Cranney
    Endocr Rev 23:570-8. 2002
    ....
  99. ncbi Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years
    J Y Reginster
    Department of Public Health Sciences, University of Liege, Liege, Belgium
    Bone 45:1059-64. 2009
    ..ranelate 2 g/day has proven efficacy against vertebral and nonvertebral fracture over 5 years in postmenopausal osteoporosis, though many women require longer-term treatment...
  100. ncbi Effect of supplementation of calcium and vitamin D on bone mineral density and bone mineral content in peri- and post-menopause women; a double-blind, randomized, controlled trial
    Nicola Di Daniele
    Human Nutrition Unit, Via Montpellier 1, University of Rome, Tor Vergata, 00173 Rome, Italy
    Pharmacol Res 50:637-41. 2004
    ..Osteoporosis is a serious global health problem for the future, that is why improving diagnostic methods and prevention of this disease could be helpful...
  101. ncbi Menatetrenone (vitamin K2) and bone quality in the treatment of postmenopausal osteoporosis
    Jun Iwamoto
    Department of Sports Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
    Nutr Rev 64:509-17. 2006
    ..Thus, available evidence supports an effect of menatetrenone on bone quality during osteoporosis treatment...

Research Grants63

  1. Signal Transduction Mechanism of Osteoclast Differentiation
    Nandini Ghosh-Choudhury; Fiscal Year: 2013
    ..formation causes bone destruction as observed in diseases such as autoimmune arthritis, periodontosis, postmenopausal osteoporosis, Padget's disease and bone tumor metastasis...
  2. IGF-1, bone turnover and response to teriparatide in premenopausal women with IOP
    Adi Cohen; Fiscal Year: 2013
    ..pilot data for a future R01 application focused on the interplay between the GH/IGF-1 axis, adipose distribution and response to TPTD in postmenopausal osteoporosis, a disease of high clinical impact that is far more common than IOP.
  3. Genetic Determinants of Physiological Responses to Fluoride in Bone
    Eric T Everett; Fiscal Year: 2012
    ..The anabolic properties of fluoride were once explored for use in the treatment of postmenopausal osteoporosis. Excessive systemic fluoride can result in calcification of soft tissues (e.g...
  4. Glucocorticoids, Bone Strength and Angiogenesis
    ROBERT STEWART WEINSTEIN; Fiscal Year: 2013
    ..factors will be elucidated in humans using archival bone biopsy specimens obtained from patients with postmenopausal osteoporosis or glucocorticoid-induced osteoporosis...
  5. Ginger Extracts in the Prevention of Metabolic Bone Disease
    LAURA ELIZABETH WRIGHT; Fiscal Year: 2011
    ..elucidate the mechanism of ginger's effect on bone in two models of metabolic bone disease, RA and postmenopausal osteoporosis. In the streptococcal cell wall (SCW)-induced arthritis model for RA, female Lewis rats will be treated ..
  6. NOVEL THERAPEUTICS FOR POSTMENOPAUSAL OSTEOPOROSIS
    Ping Men; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Postmenopausal osteoporosis is a more dangerous disease than previously thought and is one of the most common diseases in older women...
  7. OVARIECTOMY UPREGULATES BONE TURNOVER THROUGH T CELL-STROMAL CROSSTALK
    Roberto Pacifici; Fiscal Year: 2012
    ..ovx) is followed by a period of rapid bone loss which is instrumental for the development of postmenopausal osteoporosis. Ovx induced bone loss is caused by a stimulation of osteoclast (OC) number and activity insufficiently ..
  8. Role of FSH in Osreoclast Formation and Function
    Mone Zaidi; Fiscal Year: 2012
    ....
  9. Evaluation of a Novel Anti-Resorptive Therapy for Osteogenesis Imperfecta
    PATRICIA A COLLIN-OSDOBY; Fiscal Year: 2012
    ..safety profile in human subjects, and is on the verge of FDA approval for the therapeutic treatment of postmenopausal osteoporosis and other bone osteolytic conditions...
  10. Ovariectomy Induced T Cell Inflammatory Cytokines/Bone Loss in Young & Old Mice
    Roberto Pacifici; Fiscal Year: 2010
    b>Postmenopausal osteoporosis (PMO) is a frequent disease of aging women stemming from the cessation of ovarian function at menopause...
  11. The Role of PTH in the Low Bone Mass of Anorexia Nervosa
    POUNEH KHADEJEH FAZELI; Fiscal Year: 2013
    ....
  12. RANK Signaling in Osteoclast Differentiation and Function
    Xu Feng; Fiscal Year: 2013
    ..Moreover, the RANKL/RANK system is also implicated in the pathogenesis of various bone diseases such as postmenopausal osteoporosis, bone loss in rheumatoid arthritis, and tumor-induced osteolysis, a full elucidation of RANK signaling ..
  13. STUDIES OF THE FATE OF THE OSTEOCLAST
    Brendan F Boyce; Fiscal Year: 2013
    ..and remodeling and mediate bone loss in common bone diseases, including rheumatoid arthritis and postmenopausal osteoporosis, in which levels of proinflammatory cytokines, such as TNF, are increased and drive osteoclast ..
  14. Efficacy of Turmeric Extract in Prevention of Post-menopausal Osteoporosis
    Janet Funk; Fiscal Year: 2009
    ..inhibits bone resorption could offer a particularly attractive approach to the prevention of postmenopausal osteoporosis, a disease with extremely high prevalence that is essentially irreversible yet readily preventable by ..
  15. BONE PROPERTIES IN HYPOPARATHYROIDISM: EFFECTS OF PTH
    John P Bilezikian; Fiscal Year: 2013
    ..Rather, we anticipate our results will have far broader implications, including greater understanding both of the normal control of the skeleton by PTH and of the anabolic activity of PTH in the treatment of postmenopausal osteoporosis.
  16. Pathophysiology of PTH-related Protein (1-36) in Humans
    Andrew F Stewart; Fiscal Year: 2012
    ..PTHrP(1-36) in the treatment of postmenopausal osteoporosis. This is the single Specific Aim of this study: To perform a direct, head-to-head, direct comparator, ..
  17. Adiposity and Bone Loss in Spinal Cord Injury
    Leslie R Morse; Fiscal Year: 2013
    ..it is distinct in severity and pattern from other known causes of osteoporosis including disuse and postmenopausal osteoporosis. In contrast, the metaphyses of the distal femur and proximal tibia (i.e...
  18. Bone Water and Mineralization Measured by Nuclear Magnetic Resonance
    Felix W Wehrli; Fiscal Year: 2011
    ..contributes to the decline of cortical bone strength and thus increased fracture susceptibility in postmenopausal osteoporosis and, particularly, in renal osteodystrophy...
  19. Chronic Kidney Disease and PTH: Effects on the Postmenopausal Skeleton
    EMILY MARGARET STEIN; Fiscal Year: 2013
    ..They may emphasize the importance of incorporating CKD and secondary hyperparathyroidism into diagnostic and treatment strategies for postmenopausal osteoporosis.
  20. Bone Density and Circulating Mediators of Bone Metabolism in Chronic SCI
    Leslie Morse; Fiscal Year: 2009
    ..it is distinct in severity and pattern from other known causes of osteoporosis including disuse and postmenopausal osteoporosis. Currently, little is known about the cause of this bone loss or the natural history and specific ..
  21. DEGRADABLE HYDROGELS FOR ORAL DELIVERY OF CALCITONIN
    Jindrich Kopecek; Fiscal Year: 2003
    ..it is expected that for treatment of chronic disorders in non-life threatening situations, such as postmenopausal osteoporosis, parenteral administration will lead to poor patient compliance and thus restricted utility...
  22. DEGRADABLE HYDROGELS FOR ORAL DELIVERY OF CALCITONIN
    Jindrich Kopecek; Fiscal Year: 2001
    ..it is expected that for treatment of chronic disorders in non-life threatening situations, such as postmenopausal osteoporosis, parenteral administration will lead to poor patient compliance and thus restricted utility...
  23. IDIOPATHIC OSTEOPOROSIS IN PREMENOPAUSAL WOMEN
    ELIZABETH J SHANE; Fiscal Year: 2013
    ..elucidating cellular and structural mechanisms that underlie deficits in bone strength associated with postmenopausal osteoporosis, idiopathic osteoporosis (IOP) in premenopausal women, and other diseases associated with adverse ..
  24. Pathogenesis of Atypical Femur Fractures on Long Term Bisphosphonate Therapy
    D Sudhaker Rao; Fiscal Year: 2013
    ..the following specific aims: Aim 1 is to determine the prevalence of PBD and AFF in 1,000 patients with postmenopausal osteoporosis, either treated with BP for more than 2 years (500 subjects), or never BP treated (500 subjects)...
  25. Novel therapy for osteoporosis
    Emma Moore; Fiscal Year: 2009
    ..5 million fractures annually. We propose to develop a novel therapy for osteoporosis that will stimulate new bone formation. ..
  26. IN VIVO/IN VITRO STUDIES OF BONE ACIDIC GLYCOPROTEIN-75
    JEFFREY GORSKI; Fiscal Year: 1991
    ..are to: 1) determine whether the level of BAG-75 antigens (Mr+75 and/or 50 kDa) vary with onset of postmenopausal osteoporosis, hereditary osteopetrosis, and osteosarcoma in rat models; 2) purify "native" BAG-75 and the Mr=50 kDa ..
  27. Transgenic Models of Estrogen Receptor Activity in Bone
    Joseph Alexander; Fiscal Year: 2004
    ..abstract_text> ..
  28. A Novel Therapeutic Agent for Postmenopausal Bone Loss
    MERVYN WEITZMANN; Fiscal Year: 2005
    b>Postmenopausal osteoporosis results from defective bone remodeling stemming from estrogen (E2) deficiency...
  29. CALCIUM AND VITAMIN D MALNUTRITION IN ELDERLY WOMEN
    Joan Lappe; Fiscal Year: 2003
    DESCRIPTION (Adapted from the Applicant's Abstract): Postmenopausal osteoporosis is a condition of excessive skeletal fragility which results in low impact fractures...
  30. IL-6 AND ESTROGEN AND PTH INDUCED BONE RESORPTION
    Urszula Masiukiewicz; Fiscal Year: 2002
    ..Of the various subtypes of this disease, postmenopausal osteoporosis is by far the most common...
  31. MENOPAUSE, AGING & OSTEOPOROSIS--CROSS-CULTURAL INQUIRY
    Yewoubdar Beyene; Fiscal Year: 1992
    ..unique and relatively isolated control for several risk factors which are assumed to be associated with postmenopausal osteoporosis, therefore, allowing us to identify the specific role of estrogen deprivation on skeletal health...
  32. FLAXSEED PHYTOESTROGENS MAY POSITIVELY AFFECT BONE
    Bahram Arjmandi; Fiscal Year: 1999
    This proposal by an established investigator addresses topic 5: alternative to estrogen therapy. Postmenopausal osteoporosis is by far the most common cause of bone loss and therefore, a search for potential therapies is of vital concern...
  33. Magnesium Deficiency: Effect on Bone and Mineral
    Robert Rude; Fiscal Year: 2004
    ..While sex steroid deficiency is a major factor in postmenopausal osteoporosis, nutrition is also important...
  34. SPINAL CORD INJURY INDUCED OSTEOPOR0SIS
    VICKY WHITTEMORE; Fiscal Year: 1993
    ..It will also provide a basis for future studies on the effects of specific neural factors on the development of osteoporosis using other in vivo techniques (e.g immunoneutralization and infusion.)..
  35. MAGNESIUM DEFICIENCY INDUCED OSTEOPOROSIS
    Robert Rude; Fiscal Year: 1999
    ..Dietary Mg intake has been associated with bone mass and/or bone loss in aging and postmenopausal osteoporosis. Mg depletion in the rat results in decreased bone growth, osteopenia and increased skeletal fragility...
  36. TAMOXIFEN MODULATES OSTEOCLAST CA++/CALMODULIN SIGNALING
    Jay McDonald; Fiscal Year: 2001
    ..Cancer deaths in general are more prevalent in blacks than whites and postmenopausal osteoporosis in women is the major cause of approximately 1.3 million bone fractures each year...
  37. MODULATION OF LOCAL BONE TISSUE MATERIAL PROPERTIES
    Clifford Les; Fiscal Year: 2004
    ..For instance, in postmenopausal osteoporosis, there is increased turnover of bone, and a generalized loss of bone mass, but this fully explains ..
  38. MODULATION OF AGING BONE LOSS BY ANABOLIC HORMONES
    DIKE KALU; Fiscal Year: 1991
    ..Beyond the consensus that postmenopausal osteoporosis is related to ovarian hormone deficiency, there is a lack of agreement on its pathogenesis...
  39. Prevention of osteoporosis with novel bisphosphonates
    THERESA HEFFERAN; Fiscal Year: 2004
    ....
  40. ETHANOL AND OSTEOBLASTOGENESIS: ROLES OF IL-1 AND TNF
    CHARLES LUMPKIN; Fiscal Year: 2009
    ..bone metabolism indirectly by elevating the secretion of cytokines shown to be critical factors in postmenopausal osteoporosis. It has been demonstrated that cytokines mediate bone loss due to estrogen deficiency by increasing ..
  41. A Novel Post-Menopausal Osteoporosis Screening Tool
    Amit Bhattacharya; Fiscal Year: 2005
    ..The proposed study will focus on measuring natural shock absorption properties of postmenopausal osteoporosis with and without fractures and supplement information gathered from BMD measurements...
  42. Androgen deficiency and Osteopenia in Anorexia Nervosa
    Karen Miller; Fiscal Year: 2002
    ..The osteopenia that occurs in this population is unique and differs from that of postmenopausal osteoporosis. Data of surrogate markers of bone turnover have shown decreased bone formation in addition to ..
  43. INTERLEUKIN 6 AND OSTEOPOROSIS
    Evan Keller; Fiscal Year: 1999
    ..This research will also be of value because it will provide useful longitudinal data on bone density, histomorphometry and bone strength in this important animal model. ..
  44. SHEEP AS A MODEL FOR AGED HUMAN BONE
    JEROME GILBERT; Fiscal Year: 1992
    ..by carefully examining the transient process a better understanding of some of the observed features of postmenopausal osteoporosis should result...
  45. GORDON CONFERENCE--CELL AND MOLECULAR BIOLOGY OF BONES
    JOHAN HEERSCHE; Fiscal Year: 1993
    ..Cytokines and Cytokine inhibitors: Role in bone remodelling and inflammatory processes. Postmenopausal osteoporosis: the cell biology of drug treatment as deduced from histomorphometry.
  46. MECHANISMS OF AVB3 INTEGRIN MEDIATED BONE RESORPTION
    Steven Teitelbaum; Fiscal Year: 2009
    ..abstract_text> ..
  47. ALCOHOL AND OSTEOPOROSIS--AN ANIMAL MODEL
    H Sampson; Fiscal Year: 2000
    ..on bone have fairly clearly demonstrated the induction of an osteopenia which appears similar to postmenopausal osteoporosis but possibly develops by a different mechanism...
  48. EFFECT OF DIET AND PHYSICAL ACTIVITY ON PEAK BONE MASS
    Robert Recker; Fiscal Year: 1990
    ..This could result in greater skeletal mass remaining in old age and could offer protection from the crippling fractures of postmenopausal osteoporosis which afflicts nearly one half of our Caucasian women in their later years.
  49. ESTROGEN METABOLITES EFFECTS ON BONE
    Russell Turner; Fiscal Year: 2002
    ..metabolism by changes in diet or by pharmacological intervention may be a valuable tool for reducing bone loss; and 3) analogs of 16alpha-OHE1 may be useful for prevention and treatment of postmenopausal osteoporosis.
  50. TREATMENT STRATEGIES FOR OSTEOPOROSIS
    Robert Lindsay; Fiscal Year: 1992
    DESCRIPTION (Adapted from the Applicant's Abstract): At present, therapy for established postmenopausal osteoporosis is limited to antiresorptive agents which will retard further bone loss...
  51. MECHANISMS OF TNF RECEPTOR MEDIATED OSTEOCLASTOGENSIS
    Yousef Abu Amer; Fiscal Year: 2003
    ..The specific aims of the proposal are (1) to determine the mechanisms by which p55r promotes osteoclastogenesis, and (2) to determine the mechanisms by which p75r suppresses osteoclastogenesis. ..
  52. T Cells and Osteoporosis
    MICHAELA RYAN; Fiscal Year: 2006
    ..Understanding the nature and distribution of the activated T cells involved in ovx induced bone loss may ultimately lead to novel therapeutic approaches to preventing or ameliorating postmenopausal osteoporosis. [unreadable] [unreadable]
  53. Outcomes of Sleep Disorders in Older Men
    Elizabeth Barrett Connor; Fiscal Year: 2007
    ..We will also supplement the bank of MrOS specimens to allow for testing of future hypotheses concerning the role of sleep in the development of age-related diseases and conditions. ..
  54. GENDER DIFFERENCES IN OSTEOPOROSIS
    Elizabeth Barrett Connor; Fiscal Year: 2002
    ....
  55. CVD Predictors of Cognitive Function Trajectory over 20 Years
    Elizabeth L Barrett Connor; Fiscal Year: 2010
    ..This information is important given the aging of the population, the fact that CVD risk factors are modifiable, and because the maintenance of cognitive function is an essential component of healthy aging. ..
  56. Endogenous/Exogenous Sex Hormones & CHD Risk Factors
    Elizabeth Barrett Connor; Fiscal Year: 2003
    ..These observations may aid in deciding whether individual women should use HRT and, if so, which regimen would provide the most benefit with the least risk. ..
  57. A MECHANISTIC STUDY OF SKELETAL ACTIONS OF 1-34hPTH
    Robert Lindsay; Fiscal Year: 2009
    ..abstract_text> ..
  58. 6th International Symposium on Osteoporosis
    Robert Lindsay; Fiscal Year: 2005
    ..abstract_text> ..
  59. Seasonal Bone Loss in Mice
    Clifford Rosen; Fiscal Year: 2008
    ..unreadable] Understanding the impact of circadian and circannual rhythms on the skeleton will afford greater insight into homeostatic mechanisms controlling bone maintenance. [unreadable] [unreadable] [unreadable]..
  60. Determination of RDA for Vitamin D in Caucasian and African American Women
    John Gallagher; Fiscal Year: 2009
    ..The results from this study will also help in designing future larger clinical trials of the effect of vitamin D on falls and fractures. ..
  61. Bone-Sparing by Ca Salts With & Without Extra Phosphorus
    Robert Heaney; Fiscal Year: 2008
    ..1 Description, ..
  62. BONY EFFECTS OF TRANSIENT NONSKELETAL ILLNESS
    Robert Heaney; Fiscal Year: 2001
    ....
  63. Bone Turnover and Fracture Risk in Men
    Douglas Bauer; Fiscal Year: 2008
    ..These analyses will address critical questions about the pathogenesis of spine and non-spine fracture in men, and will determine the clinical utility of bone turnover measurements in this population. ..